Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

Gianella, Sara*; Marconi, Vincent C.; Berzins, Baiba; Benson, Constance A.*; Sax, Paul§; Fichtenbaum, Carl J.; Wilkin, Timothy; Vargas, Millie*; Deng, Qianqian*; Oliveira, Michelli F.*; Moser, Carlee#; Taiwo, Babafemi O.

JAIDS Journal of Acquired Immune Deficiency Syndromes: December 15, 2018 - Volume 79 - Issue 5 - p e112–e114
doi: 10.1097/QAI.0000000000001863
Letters to the Editor

*Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA

Rollins School of Public Health, Emory University, School of Medicine, Atlanta, GA

Division of Infectious Diseases, Northwestern University, Chicago, IL

§Division of Infectious Diseases, Brigham and Women's Hospital Boston, Boston, MA

University of Cincinnati Medical Center, Cincinnati, OH

Division of Infectious Diseases, Weill Cornell Medicine, New York, NY

#Department of Biostatistics, Center for Biostatistics and AIDS Research, Harvard TH Chan School of Public Health, Boston, MA

Supported by an Investigator Sponsored Study grant “Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353” from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided funding and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-Brazil.

B.O.T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/GlaxoSmithKline (GSK). V.C.M., C.J.F., C.A.B., T.W., have received grant funding for this study to their institutions through Northwestern University from ViiV/GSK. The remaining authors have no funding or conflicts of interest to disclose.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or ViiV Healthcare. HIV RNA quantification standard was obtained from the DAIDS Virology Quality Assurance (VQA) Program.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Received June 29, 2018

Accepted August 20, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.